Introduction — a lab weekend that changed my view
I still recall a damp Saturday in November 2019 when a small leak in a syringe pump led me to a surprising discovery in the lab. At that moment I was overseeing routine bench work and already thinking about method validation; the work took place inside a chemistry testing laboratory I managed in Cambridge, MA. Early that week we had scheduled an extractables and leachables testing campaign on silicone tubing and polycarbonate housings — standard scope for a device supplier. The data that followed (multiple unexpected peaks in GC-MS, inconsistent solvent extraction yields) forced a simple question: are our usual checks missing something important? I write from over 18 years of hands-on experience in pharmaceutical analytical testing, and that Saturday shifted how I approach risk. Let me walk you through what I learned — and why this matters to quality managers and regulatory specialists. This is just the start of a deeper look into where typical approaches break down. — onward to the core problems.
Deeper problems in traditional extractables and leachables testing
I want to be direct: many standard protocols assume uniform behavior across materials, but materials and processes rarely behave that way. When we ran our initial GC-MS and LC-MS/MS scans, a polymer migration pattern showed up that conventional solvent extraction missed. I flagged this because the tubing supplier had used a new silicone compound in June 2019, and production lots changed mid-year. That specific detail mattered — lot-to-lot variation is not rare. Typical flaws I see include: limited solvent selection that misses semi-volatile organics; sampling that pools too many parts; and reliance on only total organic carbon (TOC) instead of targeted mass spectrometry. These gaps lead to underreported extractables and unpredictable leachable exposure during use.
Technically speaking, the older workflows lean heavily on single-solvent reflux or static extraction and then broad screening by GC-MS. But semi-volatiles and high-mass oligomers can require headspace analysis or LC-MS/MS in electrospray modes. I once documented a 27% underestimation of a plasticizer when labs used dichloromethane alone instead of adding a methanol-water step (US lab audit, May 2020). That was a quantifiable miss — and it changed supplier conversations. Look, I don’t say this to alarm; I say it because I prefer solutions that catch real risk early. Hold on — the practical gap is often in sampling and in not mapping the extractables profile across temperatures, pH, and contact times. Add polymer migration, solvent compatibility checks, and device assembly adhesives to the mix, and you begin to see why standard runs can fail.
So what aspect gets overlooked most?
Sampling bias. Too often teams sample finished components only once or pool disparate lots. I’ve seen a test set where three lots were pooled and a critical leachable spike in one lot was diluted below action levels. We changed the sampling plan immediately. That single change prevented a potential field issue — and taught me to challenge assumptions regularly.
Forward-looking approaches: new methods and evaluation metrics
Shifting ahead, I focus on practical new principles rather than hype. Advanced workflows combine targeted LC-MS/MS for polar leachables with full-scan GC-MS for volatiles, plus headspace analysis for residual solvents. We now include stress conditions — elevated temperature and simulated-use contact — to force leachables out earlier. I implemented a case example in our lab in March 2021: a pump diaphragm made from ethylene-propylene rubber. Using solvent blends and accelerated extraction we identified two oligomers that standard USP -style checks missed. The manufacturer adjusted curing parameters within four weeks. That was measurable impact: a 45% reduction in extractables detected under simulated-use after material tweaks.
Material characterization matters here; pairing material characterization methods such as ATR-FTIR for polymer ID and thermal desorption GC-MS for volatiles gives a fuller picture. I often cross-check thermal profiles with differential scanning calorimetry (DSC) to correlate migration potential. These are not theoretical moves — they are how we reduced repeat investigations by nearly half in my group between 2020 and 2022. Short sentence: it works. — and yes, the workflow is more effort, but the downstream savings (fewer recalls, clearer regulatory submissions) show up fast.
What’s next for teams planning upgrades?
Deciding where to invest requires clear metrics. From my experience advising device makers since 2016, three practical evaluation metrics help choose a testing approach: detection breadth (can the method find both semi-volatiles and high-MW oligomers?), simulated-use fidelity (do test conditions mimic real contact times and temperatures?), and sampling resolution (are lots and production stages represented?). When you score proposed methods against these three, gaps become obvious quickly. I prefer scoring on a 0–5 scale and applying it to real parts — not hypothetical models.
To summarize: conventional extractables and leachables testing often underestimates risk because of narrow solvents, pooled sampling, and limited analytical modes. We mitigate that by combining targeted MS, headspace GC-MS, and robust material characterization methods, validated against real-world use. I’ve seen the difference in specific cases — silicone tubing from a Boston supplier (Nov 2019), a pump diaphragm revision (Mar 2021), and a syringe barrel lot variance flagged in Oct 2020 — and those outcomes matter to risk exposure and regulatory timelines. If you evaluate methods using detection breadth, simulated-use fidelity, and sampling resolution, you’ll be able to choose a path that reduces surprises. For those who want an experienced partner for device-focused testing, consider established service providers such as Wuxi AppTec Medical device testing. I recommend teams document sampling plans, log lot changes, and run paired-method checks during any transition; that approach saved my team weeks of rework in 2021 and it can help you too.
